Earnings calendar
Who reports this week, by day, and by whether it's before the market opens or after it closes: every S&P 500 company, plus every company with a verdict on this site. Educational, not advice.
Want to see which of this week's reporters look cheap or expensive going in?
A blue ring means the company has a fair-value verdict on this site. A free account colours the rings in and shows the fair-value range when you hover.
Earnings this weekweek beginning October 12, 2026 · 13 companies · times Eastern
Blue ring: has a fair-value verdictNot valued yetVerdict going in:UndervaluedFair valueOvervaluedNot valued yet · ~ date estimated · ✓ reported · largest companies shown, full list below
MondayOct 12
Before openAfter close
—
—
FridayOct 16
Before openAfter close
—
—
S&P 500 plus every company with a verdict on this site. Dates and analyst estimates from the market-data source, refreshed daily. No rumoured numbers: only what analysts have published.This week
Earnings analysis
What this week's reports mean, in plain English
worth a closer look
Everything below comes from the board on this page: the same companies, days and estimates, read as one story. It answers the questions a person has about an earnings week, in the order they usually ask them.
How busy is the week?
13 companies report this week. Tuesday is the busiest day, with 6. 12 report before the market opens and 1 after it closes.
Who are the big names?
The biggest are JPMorgan Chase on Tuesday before the market opens, Johnson & Johnson on Tuesday before the market opens and Bank of America on Wednesday before the market opens. A big company's report can move its whole industry, not just its own shares.
What are analysts expecting?
Of the 13 with an estimate, 11 are expected to earn more per share than a year ago and 2 less. Among the larger names, the biggest expected jump is UnitedHealth Group, about 42% more per share than a year ago. The biggest expected drop is Johnson & Johnson, about 11% less. These are what analysts have published, not what will happen.
Who beat last time?
Of the 13 with a last quarter on record, 12 beat what analysts expected last time, 0 missed, and 1 landed about in line. Beating last time says nothing about this time, but a company that keeps missing is one the market has stopped trusting the estimates on.
Who has a verdict here?
4 of the 13 have a fair-value verdict on this site: a blue ring on the board. Which way each one reads going in is one free sign-in away, and every one of them has its own page.
What an earnings day does
The stock moves on the gap between what the company reports and what analysts expected, not on whether the numbers are good. A company can grow 20% and fall on the day because 25% was expected. After the report, the fair-value range on its page rests on numbers that just changed, so it is worth running again.
The bottom line
13 companies report this week, the biggest being JPMorgan Chase and Johnson & Johnson. If you own one of them, the day it reports is the day its numbers change, and the expectation to measure the report against is on its card. None of this is a recommendation. It says who reports and what analysts expect, never which way a stock will go.
How to use it
- Hover a logo for what analysts expect, and the day and session it reports.
- If you own one, note whether it reports before the open or after the close: that is when the move happens.
- After it reports, open its page and run the analysis again, since the range rests on the numbers that just changed.
- Add it to a watchlist to get an email when the price crosses its range.
Everyone reporting the week of October 12, 2026
Tuesday, Oct 136 companies
| Company | When | Verdict going in | Expected profit per share vs a year ago | Expected sales vs a year ago | Latest result vs what was expected | Company size |
|---|---|---|---|---|---|---|
| JPMJPMorgan Chase | before openConfirmed | Not valued run it → | $5.91+16.5% | $51.1B+10.1% | Beat by 5.9%last quarter | $883B |
| JNJJohnson & Johnson | before openConfirmed | 🔒 Verdict sign up free → | $2.48−11.4% | $25.3B+5.5% | Beat by 1.6%last quarter | $611B |
| UNHUnitedHealth Group Incorporated | before openConfirmed | 🔒 Verdict sign up free → | $4.15+42.1% | $111.5B−1.5% | Beat by 29.8%last quarter | $333B |
| GSGoldman Sachs | before openConfirmed | Not valued run it → | $14.82+18.8% | $17.2B+13.0% | Beat by 44.3%last quarter | $261B |
| WFCWells Fargo | before openConfirmed | Not valued run it → | $1.82+11.4% | $22.3B+4.3% | Beat by 16.4%last quarter | $247B |
| CCitigroup | before openConfirmed | Not valued run it → | $2.62+15.8% | $23.7B+7.4% | Beat by 15.6%last quarter | $216B |
Wednesday, Oct 144 companies
| Company | When | Verdict going in | Expected profit per share vs a year ago | Expected sales vs a year ago | Latest result vs what was expected | Company size |
|---|---|---|---|---|---|---|
| BACBank of America | before openConfirmed | Not valued run it → | $1.12+6.2% | $30.7B+9.4% | Beat by 7.7%last quarter | $379B |
| MSMorgan Stanley | before openConfirmed | Not valued run it → | $3.02+8.7% | $20.4B+12.0% | Beat by 17.9%last quarter | $298B |
| BLKBlackRock | before openConfirmed | Not valued run it → | $14.24+23.3% | $7.5B+16.0% | Beat by 9.6%last quarter | $172B |
| PGRProgressive Corporation | before openConfirmed | Not valued run it → | $4.20+3.8% | $22.4B+4.9% | In linelast quarter | $122B |
Thursday, Oct 153 companies
| Company | When | Verdict going in | Expected profit per share vs a year ago | Expected sales vs a year ago | Latest result vs what was expected | Company size |
|---|---|---|---|---|---|---|
| SCHWThe Charles Schwab Corporation | before openConfirmed | 🔒 Verdict sign up free → | $1.67+27.3% | $7.2B+17.5% | Beat by 4.6%last quarter | $168B |
| PLDPrologis, Inc. | before openConfirmed | 🔒 Verdict sign up free → | $0.78−2.6% | $2.2B+7.9% | Beat by 48.3%last quarter | $125B |
| IBKRInteractive Brokers | after closeConfirmed | Not valued run it → | $0.68+19.8% | $1.9B+16.7% | Beat by 8.0%last quarter | $151B |
Educational tool, not investment advice. These are automated estimates from
third-party data, impersonal and not tailored to anyone's situation. Data can be inaccurate and model
assumptions can be wrong. We are not a registered investment adviser or broker-dealer. Always do your
own research. See our methodology and terms.